Retzius-Sparing Prostatectomy for Continence Recovery

Retzius-sparing prostatectomy is a robotic surgical technique that removes the prostate through a posterior route rather than the conventional front-facing approach, preserving a set of anatomical support structures that play a key role in urinary control. First described by Galfano and colleagues in 2010, the technique has gained traction because of one consistent finding across randomized trials and meta-analyses: men who undergo it regain urinary continence faster. The trade-off, and the reason this approach hasn’t simply replaced the standard method, involves a persistent question about cancer clearance at the surgical margins, particularly for tumors sitting at the front of the prostate.

How the Approach Differs from Standard Robotic Prostatectomy

In a conventional robotic-assisted radical prostatectomy, the surgeon works from the front. The space of Retzius, a fat-filled area between the pubic bone and the bladder, is opened to reach the prostate. Getting there means cutting through the puboprostatic ligaments, the endopelvic fascia, and the dorsal vein complex, all structures that help hold the urethra and bladder neck in position. That disruption is a major reason so many men leak urine for weeks or months after surgery.

The Retzius-sparing approach enters from the back. The surgeon begins by cutting through the peritoneum at the pouch of Douglas, the lowest fold of the abdominal lining behind the bladder. From there, the seminal vesicles and vas deferens are identified, and the prostate is dissected free while staying entirely behind the bladder.¹ Because the space of Retzius is never opened, the anterior support structures, including the puboprostatic ligaments and the levator ani muscle attachments, remain intact.²

Why Preserving These Structures Matters for Continence

The puboprostatic ligaments are paired fibrous bands running from the prostate’s outer covering to the underside of the pubic bone. They act as a kind of hammock for the urethra, and research going back decades has shown that sparing them speeds up the return of urinary control after prostatectomy.³ A randomized trial directly testing ligament-sparing during robotic surgery confirmed that preserving these structures helped men become continent sooner, likely because it maintained both urethral length and the suspensory mechanism that keeps the urethra from dropping after the prostate is removed.⁴

Beyond the ligaments, Retzius-sparing surgery also leaves the levator ani and nearby pelvic floor muscles undisturbed. These muscles wrap around the urethra and contribute to the active squeezing mechanism that prevents urine loss. When those fibers are left in place, the whole urethral support system functions closer to normal from day one.⁵

How Much Faster Men Regain Continence

The difference in early continence is striking. In a randomized controlled trial by Dalela and colleagues, 71% of men undergoing the Retzius-sparing approach were continent one week after catheter removal, compared with 48% in the standard approach group. The median time to continence was two days versus eight days.⁶ Another randomized trial with a full year of follow-up found a statistically better continence recovery curve in the posterior group throughout the entire 12 months.⁷

An updated meta-analysis pooling data from multiple studies confirmed the advantage at every time point measured, from immediately after surgery through one, three, six, and 12 months.⁸ The benefit is most dramatic in the first few months. By 12 months, both groups tend to converge, with continence rates in the mid-90% range. In one series, the standard approach caught up to about 93% while the Retzius-sparing group reached roughly 98%.⁹ The real clinical value, then, is about quality of life during those miserable early months, not so much about where you end up a year later.

What About Sexual Function

This is where the story gets less exciting. Despite the theoretical advantage of a gentler dissection, the Retzius-sparing technique has not shown consistent superiority for erectile function recovery. Two separate meta-analyses found no significant difference in the return of erections between the Retzius-sparing and standard approaches.¹⁰ ¹¹ The nerve bundles responsible for erections run along the back and sides of the prostate. Both approaches can spare them or damage them, depending on the surgeon’s skill and the tumor’s location. The route of entry doesn’t change the fact that the nerves are still in harm’s way during dissection.

One series did report that a higher percentage of men in the Retzius-sparing group achieved erections sufficient for intercourse at 12 months (about 87% versus 69%), but validated questionnaire scores for sexual health were nearly identical between groups.¹² That mismatch suggests the difference may reflect how men define “sufficient” rather than a measurable functional gain. At this point, anyone choosing between the two approaches primarily for sexual function recovery doesn’t have strong evidence pushing them toward the posterior route.

The Positive Surgical Margin Question

This is the concern that keeps many urologists cautious about recommending Retzius-sparing surgery universally. A positive surgical margin means cancer cells were found at the very edge of the removed tissue, raising the possibility that some cancer was left behind. A Cochrane systematic review, which represents the highest level of evidence synthesis, found that Retzius-sparing surgery may increase positive margins compared to the standard approach, based on low-certainty evidence from randomized trials.¹³ An earlier systematic review similarly found a higher rate of positive margins in the Retzius-sparing group (about 24% versus 15%), reaching statistical significance.¹⁴

Not every analysis agrees, though. Another meta-analysis found a trend toward higher margins with the Retzius-sparing approach that did not reach statistical significance, and the trend was less pronounced in higher-stage disease.¹⁵ And a third meta-analysis found no significant difference in positive margins at all.¹⁶ This inconsistency matters. It suggests that margin rates may depend heavily on surgeon experience and patient selection rather than on the technique itself.

A key question is whether higher positive margin rates actually translate to worse cancer outcomes. At least one single-surgeon series found that Retzius-sparing surgery was not independently associated with biochemical recurrence (a rise in PSA indicating possible cancer return) despite any margin differences.¹⁷ Longer follow-up data will ultimately settle this, but the existing evidence doesn’t show a clear cancer-control penalty.

Where the Tumor Sits Changes the Calculus

Because Retzius-sparing surgery approaches from behind, the front of the prostate is the last area the surgeon reaches and potentially the hardest to dissect cleanly. This has a concrete clinical consequence: when a tumor sits in the anterior part of the gland, positive margin rates climb substantially. One study found that for anterior tumors, the Retzius-sparing approach had a 53% positive margin rate versus 27% with the conventional approach. For posterior tumors, there was no such difference.¹⁸

Similarly, tumors originating in the transition zone, the inner part of the prostate closer to the urethra and the front of the gland, were independently associated with higher positive margin rates after Retzius-sparing surgery on multivariate analysis. This was especially true for high-risk patients with transition-zone tumors.¹⁹ These findings have led many experienced surgeons to recommend the Retzius-sparing approach primarily for men whose dominant tumor mass is in the posterior or lateral prostate, while flagging anterior-dominant cancers as cases where the conventional approach may be oncologically safer.

Complications and Perioperative Safety

Overall complication rates with the Retzius-sparing technique appear comparable to those of standard robotic prostatectomy. In a large series from a high-volume center tracking over 1,000 cases, the overall complication rate was about 18%, with the majority being low-grade events. The most frequent issues were urinary tract infection (roughly 4.5%), urinary retention (3.5%), and incisional hernia (about 3%). Severe, life-threatening complications were rare, occurring in 0.3% of cases, with a single perioperative death in the series (0.1%).²⁰

A focused analysis of intraoperative complications specifically found that these events were uncommon, occurring in about 2% of cases, with most graded as mild. Permanent sequelae from intraoperative events were extremely rare.²¹ In a series focused on high-risk patients, about 14% experienced postoperative complications within 90 days, with roughly 7% requiring some form of intervention, mostly percutaneous drainage of lymphoceles. No perioperative deaths were reported in that cohort either.²²

The Learning Curve for Surgeons

One practical barrier to broader adoption is that the posterior approach requires spatial orientation skills that differ from what surgeons develop during standard robotic prostatectomy training. The anatomy looks unfamiliar from behind, and the working space is tighter. A learning-curve analysis from a single surgeon showed that console times actually increased from a median of 120 minutes in the first block of cases to 150 minutes in the second block before settling back down, suggesting that surgeons initially slow down as they encounter the full range of anatomical variations the technique demands.²³

A propensity-matched comparison between younger and more experienced surgeons found that less experienced surgeons took longer at the console (about 122 versus 98 minutes on average).²⁴ This has implications for where you choose to have the procedure done. Because the margin concern already hovers over the technique, having it performed by a surgeon who has moved past the steepest part of the learning curve is especially important. Many experts recommend that surgeons be comfortable with at least 50 to 100 standard robotic prostatectomies before transitioning to the posterior approach.

Retzius-Sparing Surgery for High-Risk Cancers

Early on, many surgeons reserved the Retzius-sparing approach for lower-risk cancers where the margin question felt less consequential. That boundary has expanded. A multicenter experience involving expert surgeons performing the technique specifically in high-risk prostate cancer patients found that 89% were continent afterward, suggesting that the functional benefits hold even in more aggressive disease.²⁵ A dedicated study of high-risk and locally advanced cases likewise concluded the approach was feasible and delivered excellent continence rates, even in patients who went on to receive radiation therapy after surgery.²⁶

That last point matters because adjuvant radiation, delivered after surgery to mop up any remaining cancer cells, often worsens incontinence. A study tracking continence recovery in men who received adjuvant radiation after Retzius-sparing surgery found that the radiation did not significantly impair their continence outcomes, with recovery rates of about 81% versus 84% in the radiation and no-radiation groups at 12 months.²⁷ This resilience to postoperative radiation is one of the more compelling arguments for the technique in men who are likely to need multimodal treatment.

Unexpected Secondary Benefits

Because the space of Retzius isn’t opened, the tissue planes in the groin area remain undisturbed. This turns out to matter for inguinal hernias, a surprisingly common complication after standard robotic prostatectomy. One comparative study found that the standard approach was an independent predictor of hernia development, and the three-year hernia-free rate was roughly 94% after Retzius-sparing surgery versus about 72% after the standard approach.²⁸

Men undergoing Retzius-sparing surgery also reported less penile shortening (about 42% versus 65% in the standard group) and virtually no cases of Peyronie’s disease (acquired penile curvature), which occurred in nearly 9% of men after the standard approach.²⁹ These are quality-of-life outcomes that rarely make the headline comparisons but matter a great deal to the men living with the consequences.

The Salvage Setting

Salvage prostatectomy, performed after a prior treatment like radiation therapy has failed, is among the most technically demanding procedures in urology. The tissues are scarred and fibrotic, and incontinence rates after salvage surgery are historically much worse than after primary surgery. The Retzius-sparing approach appears to help here as well. A multi-surgeon international series found that salvage Retzius-sparing patients had substantially better continence than salvage standard patients: about 78% versus 44% achieved the zero-to-one-pad threshold, and median time to continence was 47 days versus 180 days.³⁰

A systematic review and meta-analysis of salvage cases confirmed these findings, concluding that the Retzius-sparing approach has the potential to improve continence outcomes in the salvage setting without compromising cancer clearance, though potency rates remained poor regardless of technique.³¹ A separate review reached a similar conclusion, calling salvage Retzius-sparing surgery a safe option with improved continence but low potency rates and margin and recurrence profiles comparable to the standard approach.³² For men facing salvage surgery who dread the prospect of permanent incontinence, this is a meaningful finding.

Long-Term Quality of Life and What the Scores Show

Validated patient-reported questionnaires paint a consistent picture. At 12 months, men who underwent Retzius-sparing surgery reported significantly better urinary incontinence scores and overall quality-of-life scores on the EPIC-CP questionnaire, a widely used tool that captures the patient’s own experience rather than a clinical measurement. On multivariate analysis, the Retzius-sparing technique was independently associated with those improved scores while showing no association with worse oncological outcomes.³³ A two-year assessment further confirmed that the urinary function and quality-of-life advantage persisted at every follow-up, while sexual function remained statistically similar between approaches.³⁴

The practical upshot of earlier continence goes beyond comfort. Men who regain urinary control sooner use fewer incontinence pads, return to normal activities faster, and are less likely to require secondary procedures for persistent incontinence like an artificial urinary sphincter. Those downstream savings in pads, follow-up visits, and corrective surgeries represent a real economic benefit, both to the individual patient and to healthcare systems.

Catheter Management and Early Recovery

One logistical detail that comes up for patients preparing for surgery is how urine is drained in the days after the operation. The standard approach uses a urethral catheter, which most men find uncomfortable. A comparative study within the Retzius-sparing setting tested a suprapubic tube (inserted through the lower abdomen directly into the bladder) against a standard urethral catheter. Overall postoperative pain was similar between the two, but drain-related discomfort was significantly lower with the suprapubic tube, with a median pain score of 1 versus 3.³⁵ This is an option worth discussing with your surgeon, since the posterior approach makes suprapubic tube placement straightforward, and the comfort difference during recovery is noticeable.

Longer-Term Cancer Control Numbers

Because the technique is relatively young, truly long-term survival data are still maturing. One of the larger single-center analyses, tracking 359 patients with a median follow-up of just over two years, reported three-year biochemical recurrence-free survival rates stratified by risk group. For very-low-risk cancer, the rate was about 96%; for low-risk, 82%; for intermediate-risk, 89%; for high-risk, 72%; and for very-high-risk, 71%.³⁶ These numbers are broadly in line with what would be expected from standard robotic prostatectomy across similar risk categories, which is reassuring. But the field is still waiting for five- and ten-year data comparing the two approaches head-to-head in randomized trials before anyone can state definitively that cancer outcomes are equivalent.